Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: a population-based time series analysis

Original research
par
Garg, Ria et al

Date de publication

2022

Géographie

Canada

Langue de la ressource

English

Texte disponible en version intégrale

Oui

Open Access / OK to Reproduce

Non

Évalué par des pairs

Yes

L’objectif

We assessed the impact of COVID-19, which includes the declaration of a state of emergency and subsequent release of pandemic-specific OAT guidance on the prevalence of OAT discontinuation.

Constatations/points à retenir

Following COVID-19, there was no significant change in the percentage of Ontarians who discontinued OAT, regardless of whether they were stabilized on treatment. However, mortality following OAT discontinuation must be noted, as approximately 1.4% and 0.8% of people who discontinued methadone and buprenorphine/naloxone respectively, died within 30 days of discontinuation.

La conception ou méthodologie de recherche

Population-based time series analysis

Mots clés

Transitions in care/treatment
Mortality
Substitution/OAT
About PWUD
Outcomes